5
Harleystreet Pharmaceuticals Ltd(merged)
524082 BSE
This stock has been delisted or merged and is no longer actively traded.
Harleystreet Pharmaceuticals Ltd(merged)
Healthcare Delisted BSE: 524082 Pharmaceuticals & Biotechnology
This stock has been delisted or merged and is no longer actively traded.
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has reduced debt.
- Company is almost debt free.
Weaknesses
1- Company has a low return on equity of 13.8% over last 3 years.
Growth Rate
Revenue Growth
26% higher than
3Y
Net Income Growth
56% higher than
3Y
Quarterly Results
| Particulars | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,072 | 1,179 | 1,238 | 1,306 | 1,374 | 1,445 | 1,489 | 1,568 | 1,671 | 1,742 | 1,814 | 1,823 | 1,861 |
| Expenses | 388 | 417 | 407 | 412 | 427 | 434 | 463 | 504 | 523 | 539 | 605 | 539 | 597 |
| Financing Profit | 58 | 69 | 64 | 63 | 47 | 73 | 34 | 5 | 20 | 19 | -24 | 57 | 27 |
| Fin. Margin % | 5% | 6% | 5% | 5% | 3% | 5% | 2% | 0% | 1% | 1% | -1% | 3% | 1% |
| Other Income | 95 | 122 | 107 | 107 | 124 | 136 | 143 | 205 | 184 | 219 | 236 | 186 | 221 |
| Interest | 626 | 693 | 767 | 830 | 900 | 937 | 993 | 1,059 | 1,128 | 1,184 | 1,233 | 1,227 | 1,236 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 153 | 191 | 171 | 171 | 171 | 210 | 177 | 210 | 204 | 238 | 212 | 243 | 249 |
| Tax % | 26% | 26% | 26% | 26% | 26% | 26% | 26% | 26% | 26% | 26% | 26% | 24% | 26% |
| Net Profit | 114 | 142 | 127 | 127 | 127 | 156 | 131 | 155 | 151 | 177 | 157 | 184 | 185 |
| EPS in Rs | 3.66 | 4.57 | 4.07 | 4.06 | 4.06 | 4.98 | 4.19 | 4.96 | 4.83 | 5.63 | 5 | 5.84 | 5.74 |
| Gross NPA % | 3.62% | 3.19% | 3.26% | 3.36% | 3.43% | 3.23% | 3.33% | 3.29% | 3.11% | 2.99% | 2.98% | 2.91% | 2.72% |
| Net NPA % | 1.37% | 1.04% | 1.19% | 1.28% | 1.22% | 1.11% | 1.18% | 1.17% | 1.18% | 1.12% | 1.22% | 1.21% | 1.1% |
Profit & Loss
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 |
|---|---|---|---|---|---|
| Sales | 3.76 | 3.97 | 3.68 | 4.46 | 5.63 |
| Expenses | 2.44 | 2.73 | 2.7 | 3.49 | 4.48 |
| Operating Profit | 1.32 | 1.24 | 0.98 | 0.97 | 1.15 |
| OPM % | 35.11% | 31.23% | 26.63% | 21.75% | 20.43% |
| Other Income | 0 | 0.01 | 0.01 | 0.05 | 0.06 |
| Interest | 0.1 | 0.06 | 0.07 | 0.07 | 0 |
| Depreciation | 0.4 | 0.39 | 0.44 | 0.46 | 0.46 |
| PBT | 0.82 | 0.8 | 0.48 | 0.49 | 0.75 |
| Tax % | 30.49% | 35% | 35.42% | 28.57% | 29.33% |
| Net Profit | 0.57 | 0.52 | 0.31 | 0.35 | 0.53 |
| Div. Payout % | 0% | 0% | 0% | 0% | 17.92% |
Balance Sheet
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 |
|---|---|---|---|---|---|
| Equity Capital | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 |
| Reserves | 0.88 | 1.4 | 1.71 | 2.06 | 2.47 |
| Borrowings | 0.75 | 0.73 | 0.43 | 0.03 | 0 |
| Other Liabilities | 1.05 | 1.3 | 1.53 | 2.38 | 1.92 |
| Total Liabilities | 3.63 | 4.38 | 4.62 | 5.42 | 5.34 |
| Fixed Assets | 2.9 | 3.13 | 3.57 | 3.47 | 3.27 |
| CWIP | 0.03 | 0.14 | 0 | 0.08 | 0.01 |
| Investments | 0.06 | 0.06 | 0.06 | 0.08 | 0.08 |
| Other Assets | 0.64 | 1.05 | 0.99 | 1.79 | 1.98 |
| Total Assets | 3.63 | 4.38 | 4.62 | 5.42 | 5.34 |
Cash Flow
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 |
|---|---|---|---|---|---|
| Operating | 1.11 | 0.87 | 1.06 | 0.76 | — |
| Investing | -0.33 | -0.73 | -0.74 | -0.45 | — |
| Financing | -0.75 | -0.02 | -0.3 | -0.4 | — |
| Net Cash Flow | 0.03 | 0.12 | 0.02 | -0.09 | — |
| Free Cash Flow | 0.78 | 0.14 | 0.32 | 0.33 | — |
| CFO/OP | 108 | 92 | 124 | 95 | — |
Ratios
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 |
|---|---|---|---|---|---|
| Debtor Days | 9.71 | 8.27 | 14.88 | 11.46 | 14.91 |
| Inventory Days | 94.9 | 141 | 130 | 120 | 77.15 |
| Days Payable | 329 | 294 | 384 | 199 | 134 |
| Cash Conversion Cycle | -224 | -145 | -239 | -67.35 | -41.47 |
| Working Capital Days | -46.6 | -38.61 | -71.41 | -58.92 | -2.59 |
| ROCE % | — | 30.39% | 17.83% | 17.94% | 23.22% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Harleystreet Pharmaceuticals Ltd(merged) insights
42 extracted metrics + investor summaries across FY06–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Change in Directorate
6h - Appoint Pushan Mahapatra as independent director from Mar 10, 2026; recommended as Non-Executive Part-Time Chairman; three-year term. 6h - Appoint Pushan Mahapatra as independent director from Mar 10, 2026; recommended as Non-Executive Part-Time Chairman; three-year term.
2
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
26 Feb - DCB Bank participated in Kotak Securities investor conference on Feb 26, 2026; schedule of 14 meetings shared. 26 Feb - DCB Bank participated in Kotak Securities investor conference on Feb 26, 2026; schedule of 14 meetings shared.
3
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
18 Feb - Of Analysts / Institutional Investors Meeting under Regulation 30 of the SEBI (LODR) Regulations, 2015 ('SEBI Listing Regulations') Date: February 26, 2026 Kotak Securities Limited … 18 Feb - Of Analysts / Institutional Investors Meeting under Regulation 30 of the SEBI (LODR) Regulations, 2015 ('SEBI Listing Regulations') Date: February 26, 2026 Kotak Securities Limited …
4
Announcement under Regulation 30 (LODR)-Change in Directorate
17 Feb - Reappointment of Krishnan S. Seshadri as Whole Time Director from 13 Jun 2026 to 12 Jun 2027, subject to RBI. 17 Feb - Reappointment of Krishnan S. Seshadri as Whole Time Director from 13 Jun 2026 to 12 Jun 2027, subject to RBI.
5
Announcement under Regulation 30 (LODR)-Change in Directorate
17 Feb - Appointment of Neeta Sudhir Rege as independent director effective Feb 18, 2026 for three years, subject to shareholder approval. 17 Feb - Appointment of Neeta Sudhir Rege as independent director effective Feb 18, 2026 for three years, subject to shareholder approval.
Frequently Asked Questions about Harleystreet Pharmaceuticals Ltd(merged)
Where is Harleystreet Pharmaceuticals Ltd(merged) (524082) listed?
Harleystreet Pharmaceuticals Ltd(merged) trades under code 524082 on the BSE.
Which sector does Harleystreet Pharmaceuticals Ltd(merged) belong to?
Harleystreet Pharmaceuticals Ltd(merged) is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524082.md for Harleystreet Pharmaceuticals Ltd(merged): company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.